Poster Session

Start Date

20-5-2016 12:30 PM

Document Type

Poster Abstract

Description

Introduction Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm that has been associated with a number of genetic mutations, most commonly TET2 mutations in up to 50-60% of cases. Mutations in epigenetic genes such as TET2 are known to disrupt the conversion of 5-methycytosine to 5-hydroxymethylcytosine (5hmC), contributing to oncogenesis. We hypothesized that CMML cases would exhibit decreased 5hmC expression, reflecting the propensity for TET2 mutations in CMML. We also sought to determine whether 5hmC IHC status reflected disease severity in terms of progression to AML and overall patient survival.

Methods Thirty-five cases of CMML from between 1/2006 and 12/2014 were identified from the pathology archives at UMass, under an IRB-approved protocol. IHC was performed on FFPE bone marrow biopsy specimens with an anti-5hmC antibody. Staining was scored based on intensity of nuclear staining: 0 (neg) to 3+ (strong); and proportion of cells staining: 0 ( < 1%), 1 (1-25%), 2 (26-50%), 3 (51-75%), 4 ( > 76%). A combined product score was calculated yielding scores of 0-12. Correlation to clinical parameters (age, blast count, progression to AML, and overall patient survival) was investigated.

Results 60% (21/35) of CMML cases showed low expression of 5hmc (combined score < =4). This loss of 5hmC expression correlated significantly with poorer overall survival in Kaplan-Meier curves (p=0.0287). There was no significant correlation between 5hmC score and patient age, blast count, or AML progression.

Conclusion IHC detection of 5hmC in CMML is significantly correlated with patient overall survival and could potentially be utilized as a prognostic biomarker. Loss of 5hmC expression likely reflects mutations to epigenetic pathways and could be useful in guiding treatment with hypomethylating agents.

Keywords

Chronic Myelomonocytic Leukemia, TET2 mutations

Creative Commons License

Creative Commons Attribution-Noncommercial-Share Alike 3.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.

Share

COinS
 
May 20th, 12:30 PM

5-Hyroxymethylcytosine Immunohistochemical Staining Correlates with Overall Survival in Patients with Chronic Myelomonocytic Leukemia

Introduction Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm that has been associated with a number of genetic mutations, most commonly TET2 mutations in up to 50-60% of cases. Mutations in epigenetic genes such as TET2 are known to disrupt the conversion of 5-methycytosine to 5-hydroxymethylcytosine (5hmC), contributing to oncogenesis. We hypothesized that CMML cases would exhibit decreased 5hmC expression, reflecting the propensity for TET2 mutations in CMML. We also sought to determine whether 5hmC IHC status reflected disease severity in terms of progression to AML and overall patient survival.

Methods Thirty-five cases of CMML from between 1/2006 and 12/2014 were identified from the pathology archives at UMass, under an IRB-approved protocol. IHC was performed on FFPE bone marrow biopsy specimens with an anti-5hmC antibody. Staining was scored based on intensity of nuclear staining: 0 (neg) to 3+ (strong); and proportion of cells staining: 0 ( < 1%), 1 (1-25%), 2 (26-50%), 3 (51-75%), 4 ( > 76%). A combined product score was calculated yielding scores of 0-12. Correlation to clinical parameters (age, blast count, progression to AML, and overall patient survival) was investigated.

Results 60% (21/35) of CMML cases showed low expression of 5hmc (combined score < =4). This loss of 5hmC expression correlated significantly with poorer overall survival in Kaplan-Meier curves (p=0.0287). There was no significant correlation between 5hmC score and patient age, blast count, or AML progression.

Conclusion IHC detection of 5hmC in CMML is significantly correlated with patient overall survival and could potentially be utilized as a prognostic biomarker. Loss of 5hmC expression likely reflects mutations to epigenetic pathways and could be useful in guiding treatment with hypomethylating agents.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.